#Sweden #Stockholm #Sobi #Incentive Programs #Swedish Orphan Biovitrum

Sobi's Share Buyback Plan: Ensuring Commitment Fulfillment

Swedish Orphan Biovitrum AB (Sobi) is taking strategic steps to support its incentive programs through a planned share repurchase. During its Annual General Meeting held on May 8, 2025, the board exercised the authorization needed to repurchase class C shares. This decision not only aims to secure the company's long-term commitments to its incentive programs but also reflects Sobi’s commitment to its shareholders.

Details from the Annual General Meeting

All resolutions made during the meeting reinforce Sobi's dedication to enhancing shareholder value. The meeting resulted in approval for the issuance of a maximum of 1,412,788 redeemable and convertible class C shares, intended specifically for fulfilling obligations connected to long-term incentive programs. Such actions demonstrate Sobi's proactive approach to maintaining its financial commitments while fostering trust with its workforce and investors alike.

The board has also been given the authority to repurchase the existing class C shares. This initiative will take place over an extended period, set between July 16 and November 7, 2025. The shares will be bought back at a price fluctuating between 100% and 105% of their quotient value, ensuring that the buyback is conducted at a fair market value for its shareholders.

Repurchase Mechanics

Sobi's Board of Directors authorized the immediate repurchase of class C shares priced at approximately SEK 0.55 each, following the subscription and payment arrangement with Svenska Handelsbanken AB. Importantly, upon completion of this buyback, all repurchased class C shares will be converted into common shares. This conversion aims to increase the total number of common shares in Sobi's possession, which follows the repurchase of additional shares to a total of 12,790,468 common shares.

Sobi: A Leader in Rare Disease Treatment

Sobi has firmly established itself as a pivotal player in the biopharmaceutical sector, unlocking breakthrough innovations to improve the lives of those affected by rare diseases. With a workforce of approximately 1,900 employees distributed across major regions including Europe, North America, and Asia, Sobi reported impressive revenue of SEK 26 billion in 2024, reflecting its strong market position.

Sobi's shares (STOSOBI) are publicly traded on Nasdaq Stockholm, providing opportunities for investors to engage with this thriving biopharma company. As it continues to advocate for rare disease communities, Sobi exemplifies the ongoing commitment to innovation and stakeholder engagement.

For those interested in keeping track of Sobi's investor relations, the company maintains updated resources online and on LinkedIn. This enables interested parties to stay informed about the latest developments, including the implications of their strategic decisions on market performance.

Conclusion

The recent resolutions passed at Sobi's Annual General Meeting signal a robust strategy aimed at fortifying investor trust and fulfilling incentive commitments. As the company embarks on its share repurchase plan, stakeholders can expect Sobi to maintain its focus on innovation and long-term growth in the biopharmaceutical landscape.